Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein
Sign Up to like & getrecommendations! Published in 2023 at "Viruses"
DOI: 10.3390/v15051195
Abstract: Canocapavir is a novel antiviral agent with characteristics of core protein allosteric modulators (CpAMs) that is currently in a phase II clinical trial for treatment of hepatitis B virus (HBV) infection. Herein, we show that… read more here.
Keywords: core protein; hbv; linker region; canocapavir ... See more keywords